Connect with others who understand.

Sign up Log in
Quick Links
Q&A Treatments A-Z Help Center Guidelines Crisis Accessibility
Resources
Emotional Well-Being Living with Myeloma Myeloma Condition Information Myeloma Symptoms Myeloma Treatments All Resources
About MyMyelomaTeam
What is This Site Terms of Use Privacy policy
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

1. Which Is The Best Maintainence Therapy In Myloma Standard Risk With Creatine 2.0 ,daratumab Phospro Or Relivimid (lenolidamide)

A MyMyelomaTeam Member asked a question 💭
San Francisco, CA
September 16
•
Be the first to like/hug
A MyMyelomaTeam Member

For standard-risk multiple myeloma, lenalidomide (Revlimid) is the current standard of care used in maintenance therapy. Studies have shown that lenalidomide can significantly improve progression-free survival and sustain remission after stem cell transplant for around 57 months compared to 30 months without maintenance Show Full Answer

For standard-risk multiple myeloma, lenalidomide (Revlimid) is the current standard of care used in maintenance therapy. Studies have shown that lenalidomide can significantly improve progression-free survival and sustain remission after stem cell transplant for around 57 months compared to 30 months without maintenance treatment.

However, it's important to discuss with your oncologist to tailor the treatment plan to your specific health needs, including your creatinine levels and any other individual factors.

September 16

Related content

View All

Is Darzalex Phospro Best For Post BMT Standard Risk Multiple Myeloma With Renal Problem Maintence Therapy

A MyMyelomaTeam Member asked a question 💭
San Francisco, CA
June 8

What Dose Quantity Of Lenalidomide Is Recommended Under Standard Risk Myeloma With Creatinine 2.0

A MyMyelomaTeam Member asked a question 💭
San Francisco, CA
September 16

Clinical Trials

A MyMyelomaTeam Member asked a question 💭
Spain, Alicante
March 9, 2019
What Is Minimal Residual Disease in Myeloma?
Immunotherapy for Multiple Myeloma: What To Know
Multiple Myeloma Maintenance Therapy: 6 Facts
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in